Do Traders Think Hepion Pharmaceuticals Inc (HEPA) Can Turn Around Tuesday?

Overall market sentiment has been high on Hepion Pharmaceuticals Inc (HEPA) stock lately. HEPA receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Hepion Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on HEPA!

See Full HEPA Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With HEPA Stock Today?

Hepion Pharmaceuticals Inc (HEPA) stock has fallen -9.24% while the S&P 500 is higher by 1.89% as of 1:35 PM on Tuesday, Nov 14. HEPA is lower by -$0.32 from the previous closing price of $3.45 on volume of 90,284 shares. Over the past year the S&P 500 has gained 13.58% while HEPA is lower by -60.92%. HEPA lost -$12.01 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Hepion Pharmaceuticals Inc click here.

More About Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. Click Here to get the full Stock Report for Hepion Pharmaceuticals Inc stock.